Michael Brown, MD
Interventional Cardiology · Columbia, MONPI 1760500987
Payments from drug & device makers
Across 488 payments — averaging $81.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$31K
- Abbott$1K
- Biotronik Inc.$1K
- Medtronic$895
- Amgen$842
- Boston Scientific$493
- plus $4K from 31 others
What the payments were for
- Consulting fees$4,50027%
- Travel & lodging$2,74916%
- Food & beverage$9,41456%
- Gifts$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 68 | $30,761 |
| Abbott | 66 | $1,170 |
| Biotronik Inc. | 14 | $1,057 |
| Medtronic(2 entities) | 53 | $895 |
| Amgen | 74 | $842 |
| Boston Scientific | 7 | $493 |
| Novartis | 35 | $476 |
| Johnson & Johnson | 22 | $461 |
| Edwards Lifesciences | 29 | $416 |
| Shockwave Medical, Inc | 12 | $391 |
| Angiodynamics, Inc. | 9 | $355 |
| Abiomed | 6 | $339 |
| Bayer | 11 | $188 |
| E.r. Squibb & Sons, L.L.C. | 10 | $183 |
| Cardiovascular Systems Inc. | 8 | $161 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $129 |
| AstraZeneca | 8 | $128 |
| Pfizer | 7 | $124 |
| Philips North America LLC | 6 | $122 |
| Merck | 7 | $112 |
| Bard Access Systems, Inc. | 2 | $111 |
| Novo Nordisk | 5 | $108 |
| Stryker | 1 | $96 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $68 |
| Livanova USA, Inc. | 1 | $55 |
| Acist Medical Systems, Inc. | 1 | $50 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $29 |
| Chiesi USA, Inc. | 2 | $28 |
| Boehringer Ingelheim | 1 | $21 |
| Cardinal Health 200 LLC | 1 | $21 |
| BD | 1 | $19 |
| Atricure, Inc. | 1 | $18 |
| B. Braun Interventional Systems Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$11,862
- FLOWTRIEVER CATHETER, S$3,448
- BioMonitor$476
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$211
- Impella$150
- ONYX FRONTIER$147
- FlowTriever$146
- ClotTriever$146
- XARELTO$146
- AVVIGO Guidance System$141
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- Auryon Laser System 100-120 Vac$125
How this compares
$39,526 in reported general payments places this provider in the 70th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 447 | $433,813 |
| Repatha SureclickEvolocumab | 120 | $166,777 |
| AdempasRiociguat | 12 | $162,687 |
| EntrestoSacubitril/Valsartan | 131 | $132,246 |
| XareltoRivaroxaban | 107 | $87,930 |
| CamzyosMavacamten | 11 | $83,971 |
| Praluent PenAlirocumab | 48 | $51,000 |
| FarxigaDapagliflozin Propanediol | 51 | $37,258 |
| Atorvastatin Calcium | 815 | $7,258 |
| Cilostazol | 384 | $6,281 |
| ClopidogrelClopidogrel Bisulfate | 711 | $4,802 |
| Carvedilol | 523 | $3,639 |
| Prasugrel Hcl | 44 | $3,202 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 66 | $2,585 |
| Rosuvastatin Calcium | 157 | $2,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $124 | $433,813447 claims |
| BayerAdempas | $188 | $162,68712 claims |
| NovartisEntresto | $476 | $132,246131 claims |
| Johnson & JohnsonXarelto | $461 | $87,930107 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $183 | $83,97111 claims |
| AstraZenecaFarxiga | $128 | $37,25851 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Columbia
- Kul AggarwalColumbia$523K
- Taishi HiraiColumbia$310K
- Poorna KaruparthiColumbia$245K
- Albert ChanColumbia$91K
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.